Finance

Lists
KRRO:NASDAQ
Korro Bio Inc
14,96 USD
+1,42%
(+0,21) 1D
14,96 USD
0,00% (0,00)
After hours
Closed: 9-ноя., 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KRRO...
Open
15,14 USD
High
16,00 USD
Low
14,52 USD
Mkt. cap
220,30 млн
Avg. vol.
206,26 миң
Volume
170,17 миң
52-wk high
36,79 USD
52-wk low
5,20 USD
EPS
-10,00 USD
Beta
3,23
Shares outstanding
13,73 млн
No. of employees
58
Open
15,14 USD
High
16,00 USD
Low
14,52 USD
Mkt. cap
220,30 млн
Avg. vol.
206,26 миң
Volume
170,17 миң
52-wk high
36,79 USD
52-wk low
5,20 USD
EPS
-10,00 USD
Beta
3,23
Shares outstanding
13,73 млн
No. of employees
58
News stories
From web sources and news partners
Pharmaceutical Executive
Pharmaceutical Executive
·
3 күн мурун
Novo Terminates Research Collaboration With Korro Bio
About Korro Bio Inc
CEO-
Employees58
Founded2014
Headquarters-
SectorHealth Care
Industry-
Websitekorrobio.com
Analyst ratings
Based on 6 analysts giving stock ratings to KRRO in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for KRRO in the last 3 months.
Highest
Current 14,96 USD
30,00 USD (+100,53%)
Average
19,83 USD (+32,55%)
Lowest
10,00 USD (-33,16%)
Analyst
Recommendation
Action
Price target
Projected
Date
Luca Issi
RBC Capital
Hold
Maintained
10,00 USD
-33,2%
11/05/2026
Yigal Nochomovitz
Citi
Buy
Reiterated
21,00 USD
+40,4%
11/05/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
15,00 USD
+0,3%
11/06/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
22,00 USD
+47,1%
10/28/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
30,00 USD
+100,5%
10/06/2026
Unknown Analyst
LifeSci Capital
Buy
Maintained
21,00 USD
+40,4%
10/06/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
22,00 USD
+47,1%
10/06/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
22,00 USD
+47,1%
08/06/2026
William Maughan
Clear Street
Buy
Maintained
18,00 USD
+20,3%
08/07/2026
Myles Minter
William Blair
Buy
Maintained
-
-
08/06/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
15,00 USD
+0,3%
08/06/2026
Catherine Novack
JonesTrading
Buy
Upgraded
23,00 USD
+53,7%
05/08/2026
Ryan Deschner
Raymond James
Buy
Upgraded
23,00 USD
+53,7%
03/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
1,29 млн
-
-
-
Cost of goods sold
8,60 млн
11,53 млн
11,63 млн
10,16 млн
Cost of revenue
8,60 млн
11,53 млн
11,63 млн
10,16 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8,58 млн
8,91 млн
8,48 млн
8,29 млн
Operating expense
8,58 млн
8,91 млн
8,48 млн
8,29 млн
Total operating expenses
17,18 млн
20,44 млн
20,11 млн
18,46 млн
Operating income
-15,88 млн
-20,44 млн
-20,11 млн
-18,46 млн
Other non operating income
990,00 миң
-
-
-
EBT including unusual items
-49,41 млн
-19,53 млн
-18,81 млн
-17,29 млн
EBT excluding unusual items
-14,89 млн
-19,53 млн
-18,81 млн
-17,29 млн
Income tax expense
636,00 миң
95,00 миң
108,00 миң
260,00 миң
Effective tax rate
-1,29%
-0,49%
-0,57%
-1,50%
Other operating expenses
-
-
-
-
Net income
-50,04 млн
-19,62 млн
-18,92 млн
-17,55 млн
Net profit margin
-3 873,22%
-
-
-
Earnings per share
-1,65
-1,69
-1,07
-0,98
Interest and investment income
-
906,00 миң
1,30 млн
1,17 млн
Interest expense
-
-
-
-
Net interest expenses
-
906,00 миң
1,30 млн
1,17 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-15,23 млн
-20,06 млн
-19,74 млн
-18,10 млн
Gain or loss from assets sale
-18,00 миң
-
-
7,00 миң
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору